Divozilimab vs Ocrevus Zunovo

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

Divozilimab · Ivlizi

Marketed by Biocad

Phase 3 in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT05385744 · Phase 3 · completed

Randomized, double-blind, active-controlled Phase 3 trial (338 patients randomized 1:1) showing superior relapse reduction vs teriflunomide (PMID 38676683).

Reported efficacy

Annualized Relapse Rate (ARR): Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 (met)

Result source: NCT05385744

Ocrevus Zunovo

Marketed by Roche

Approved in Multiple Sclerosismonoclonal antibody + enzyme
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDivozilimabOcrevus Zunovo
Annualised relapse rate—Not posted · NCT05385744—Not reported
Free of 3-month confirmed disability progression (%)—Not posted · NCT05385744—Not reported
New or enlarging T2 lesions—Not posted · NCT05385744—Not reported

Annualised relapse rate

Divozilimab
—Not posted · NCT05385744
Ocrevus Zunovo
—Not reported

Free of 3-month confirmed disability progression (%)

Divozilimab
—Not posted · NCT05385744
Ocrevus Zunovo
—Not reported

New or enlarging T2 lesions

Divozilimab
—Not posted · NCT05385744
Ocrevus Zunovo
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Ocrevus Zunovo: registry results are on file for Multiple Sclerosis, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Divozilimab

Annualized Relapse 0.05 per year
event rate · per year
No placebo or comparator arm
NCT05385744 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ocrevus Zunovo's landscape